Tag Archives: biotech industry

Debunking Ag Biotech’s Top 5 Myths

Book

On Reason.com, award-winning science correspondent Ronald Bailey takes on the Institute for Responsible Technology (IRT), an organization opposed to crop biotechnology. IRT published a list of reasons to avoid GMOs. Bailey says, “it’s a mish-mash of misinformation and disinformation. All of the institute’s assertions are unfounded.” In a detailed article chock full of scientific cites, Bailey debunks the following IRT Myths: 1. “GMOs Are Unhealthy” 2. “GMOs Increase Herbicide Use” 3. “Genetic Engineering Creates Dangerous Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

BIO-Europe Spring Opening Remarks

Chart

BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring conference in Barcelona yesterday. His slides provide a snapshot of the biotech industry’s performance and highlight emerging trends in venture exits: IPOs and M&A. Takeaways from his talk include breakouts on multiple fronts for the industry: FDA approvals at highs not seen since the 1990s Orphan designation approvals at all-time highs IPOs starting to show signs of life in 2012 Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Despite Low Funding, Biotech Productivity Remains High In 2013

John Milligan

At the 2013 BIO CEO & Investor Conference, John Milligan, President and COO of Gilead Sciences, spoke in a standing room only fireside chat with Joel Sendek, Managing Director of Stifel Nicolaus, who moderated the discussion. Nicolaus noted that Gilead’s market cap has grown at an astounding 40 fold over the past 15 years, and asked Milligan to speak about the current state of the biotech industry. Milligan explained that biotech is not becoming more Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Word on the Street – Biotech Stocks Only Have Room to Go Up

The Opening Lunch Plenary at this year’s BIO CEO & Investor Conference was a lively discussion between portfolio managers and senior buy-side analysts looking to forecast the year ahead in biotech. BIO’s own, Celia Economides, Director, Investor Relations & Programs, reminded us all where we were 15 years ago at the inception of this event. At the 1999 event, there were 18 presenting companies, zero 1X1 meetings scheduled and 271 attendees.  As of day one, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Biobuck M&A in Full Gear

Graph

The 2012 M&A results are in and trends are mixed. Last year was a down year in terms of total acquisitions and total dollar value amounts vs 2011.  What was not down however was the earnout structures embedded in these deals. More and more M&A transactions are looking like partnering deals structured with CVRs accounting for the bolus of the reported purchase price. Here is a look at therapeutic-focused acquisitions (valued at >$10M) over the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,